Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Inc. announced that the U.S. Food and Drug Administration scheduled the New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee on May 24, 2017. Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.

Read More »

Lots of sleep tied to worse breast cancer survival odds

Women with breast cancer who sleep at least nine hours a night may be more likely to die from their tumors than patients who get just eight hours of rest, a recent study suggests.

Read More »

Breast cancer drug combo succeeds key study

Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.

Read More »

Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer’s Ibrance

Novartis won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer’s Ibrance.

Read More »

Mylan gains clear pathway for Herceptin biosimilar

Mylan reached a settlement providing “a clear pathway” for the launch of its biosimilar version of Roche’s top-selling breast cancer drug Herceptin in major markets.

Read More »

Roche drug cocktail cuts breast cancer deaths

Roche’s bid to shield its lucrative oncology franchise from generics got a lift from a trial showing a new drug cocktail kept breast cancer patients alive longer.

Read More »

LYNPARZA Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer

AstraZeneca announced positive results from its Phase III OlympiAD trial comparing LYNPARZA (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.

Read More »

Immunomedics, Seattle Genetics ink $2 billion deal

Drug developer Immunomedics Inc. entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.

Read More »

Natural Compound Found in Herbs, Vegetables Could Improve Treatment of Triple-Negative Breast Cancer in Women

University of Missouri researchers have found that luteolin, a natural compound found in herbs such as thyme and parsley, and vegetables such as celery and broccoli, could reduce the risk of developing metastasis originating from triple-negative breast cancer in women.

Read More »

Benefits of new cancer drugs vary widely

Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom